Eric Crombez, M.D., serves as the Chief Medical Officer and Executive Vice President at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultrarare genetic diseases. Dr. Crombez brings a wealth of experience in clinical development and medical affairs, particularly in the realm of rare diseases. He joined Ultragenyx in 2019, quickly rising to his current leadership position, where he oversees the company's clinical development strategy and execution, ensuring that innovative therapies reach patients in need. Prior to joining Ultragenyx, Dr. Crombez held several key roles that honed his expertise in rare disease therapeutics. He was the Senior Vice President and Head of Clinical Development at BioMarin Pharmaceutical Inc., where he played a pivotal role in advancing treatments for rare genetic disorders. Before BioMarin, he worked at Genzyme Corporation, contributing to the development of therapies for lysosomal storage disorders. Dr. Crombez's academic credentials are equally impressive; he earned his medical degree from the University of Pennsylvania and completed his residency and fellowship training at the University of California, San Francisco. His dedication to improving patient outcomes through cutting-edge research and compassionate care has been a hallmark of his career. In his role at Ultragenyx, Dr. Crombez is instrumental in driving the company's mission to deliver life-changing therapies to patients with rare genetic diseases. He leads a team of dedicated professionals in navigating the complex landscape of clinical trials and regulatory approvals, ensuring that Ultragenyx's pipeline of innovative treatments progresses efficiently. Under his leadership, the company has achieved significant milestones, including the successful development and approval of treatments like Crysvita for X-linked hypophosphatemia and Dojolvi for long-chain fatty acid oxidation disorders. Dr. Crombez's strategic vision and commitment to scientific excellence continue to propel Ultragenyx forward, making a profound impact on the lives of patients worldwide.